[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"end-stage-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:end-stage-liver-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,49,79,127,155,197,222,249,279,298,324,347,369,393,421,449,473,497,520,540],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100632851","effect-of-preoperative-oral-carbohydrate-loading-on-postoperative-outcomes-in-liver-transplant-patients-100632851",false,"NCT07519057","Effect of Preoperative Oral Carbohydrate Loading on Postoperative Outcomes in Liver Transplant Patients","Effect of Preoperative Oral Carbohydrate Loading on Postoperative Outcomes in Liver Transplant Patients: A Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n* age ≥ 18 years\n* elective liver transplantation at the Department of General, Transplant, and Liver Surgery, Medical University of Warsaw\n* grafts from brain-dead donors\n* MELD score \\\u003C35\n\nExclusion Criteria:\n\n* acute liver failure\n* insulin-dependent diabetes mellitus\n* gastroparesis\n* mechanical bowel obstruction\n* liver retransplantation within less than 6 months of the primary transplant","ALL","18 Years",{"count":19,"type":20},434,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of the study is to evaluate the effect of preoperative oral carbohydrate loading on postoperative outcomes in liver transplant recipients. The results of this study may contribute to improving recovery after liver transplantation and shortening postoperative hospital stay in these patients.\n\nParticipants will be randomly assigned to either the study group or the control group. Patients assigned to the study group will receive 400 mL of a carbohydrate beverage (Nutricia preOp®), to be consumed up to 2 hours before the anesthesia induction. Patients assigned to the control group will receive 400 mL of a placebo administered in an identical manner as in the study group. Participants will not be informed which group they have been assigned to.\n\nIn the postoperative period, routine laboratory and imaging tests will be performed, and their results will be used to assess the effects of the intervention. Follow-up of the patient's clinical course is planned for up to 30 days after surgery. The schedule of follow-up visits will not differ from standard clinical practice.",[26,27,28,29],"Liver Transplantation","Liver Transplant","Liver Transplant Surgery","End Stage Liver Disease",[31,32,33,26,27,34,35],"Preoperative Oral Carbohydrate Loading","POCL","Nutricia PreOp","Carbohydrate drink","Preoperative Carbohydrate Loading","RECRUITING","2026-06-01",{"date":39,"type":40},"2026-06-03","ACTUAL",{"date":42,"type":40},"2026-05-27",{"date":44,"type":20},"2028-08",{"name":46,"class":47},"Medical University of Warsaw","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100526552","testing-liverwatch-a-home-based-remote-monitoring-intervention-for-advanced-liver-disease-100526552","NCT06136221","Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease","Inclusion Criteria:\n\n* English speaking\n* Aged 18 years or older\n* Home-dwelling\n* Diagnosis of cirrhosis- Child Turcotte-Pugh (CTP) B or C or a complication in the past 6 months (CTP B or higher, hepatic encephalopathy, variceal bleeding, fluid overload, liver-related hospitalization, or requiring symptom management with diuretics, non-absorbable disaccharides, rifaximin, nonselective beta blockers)\n* Patient and\u002For caregiver is able and willing to receive SMS text messages\n* Willing and able to wear personal fitness trackers and engage with study staff\n\nExclusion Criteria:\n\n* No access to a smartphone\n* Non-home dwelling\n* On hospice care\n* Model for end stage liver disease (MELD) score ≥30\n* Advanced hepatocellular carcinoma, BCLC C or higher\n* Hospitalization within the last 30 days\n* Deemed not appropriate by treating physician for medical reasons\n* Enrolled in other dietary or physical activity interventions\n* Receiving physical therapy as standard of care",{"count":56,"type":20},110,[23],"Remote healthcare monitoring for cirrhosis has shown promise in overcoming barriers to accessing specialty care, improving healthcare quality, and reducing mortality. The LiverWatch study is investigating whether a remote nutrition, physical activity, and education intervention can improve health outcomes in those with cirrhosis. In this clinical trial, individuals will be randomized to either enhanced usual care or the LiverWatch intervention. Both groups are given fitbits and asked to increase their step counts. Those in the Liverwatch group will be incentivized for increase their physical activity while also undergoing a personalized nutrition intervention and weekly symptom monitoring and cirrhosis education.",[60,61,62,63,64],"Cirrhosis, Liver","End Stage Liver DIsease","Symptoms and Signs","Physical Inactivity","Muscle Loss",[66,67,68],"Telehealth","Remote Symptom Monitoring","Gamification","2026-05-07",{"date":71,"type":40},"2026-05-11",{"date":73,"type":40},"2024-05-01",{"date":75,"type":20},"2027-05-31",{"name":77,"class":47},"University of Pennsylvania",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":78},"100636088","nutrition-and-exercise-prehabilitation-in-patients-awaiting-liver-transplantation-100636088","NCT07561138","Nutrition and Exercise Prehabilitation in Patients Awaiting Liver Transplantation","Evaluation of Protein Distribution Optimization With Exercise Regimen on Nutritional Status, Body Composition and Functional Status in Patients Awaiting Liver Transplantation: The POWER-LT Randomized Clinical Trial","POWER-LT","Inclusion Criteria:\n\n* End-stage liver disease, diagnosed by transient elastography (FibroScan) or imaging-based evaluation with compatible clinical picture\n* Referred for liver transplantation and evaluated to have a high likelihood of being listed, according to primary hepatologist assessment, or already listed for liver transplantation\n* No prior formal dietary advice\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Estimated waiting time for liver transplantation \\\u003C 3 months\n* Estimated life expectancy \\\u003C 3 months\n* Chronic kidney disease requiring protein restriction\n* Exercise contraindicated (e.g., active or recent variceal bleeding, severe grade of hepatic encephalopathy, refractory ascites, etc.)\n* Unstable or severe psychiatric disorder\n* Pregnancy or lactation\n* Inability to provide written informed consent","70 Years",{"count":89,"type":20},90,[23],"This study aims to evaluate the effects of a diet with even protein distribution plus exercise (Group A) versus a diet with skewed protein distribution plus exercise (Group B) versus standard dietary and physical activity advice (Group C) on nutritional status, body composition and functional status in patients awaiting liver transplantation.",[93,94,26,95,96,97],"End-stage Liver Disease","Liver Cirrhosis","Malnutrition","Sarcopenia","Frailty",[99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117],"liver disease","end-stage liver disease","liver cirrhosis","liver transplantation","malnutrition","sarcopenia","frailty","diet","nutrition","nutrition therapy","protein","protein distribution","exercise","prehabilitation","nutritional status","body composition","functional status","physical performance","quality of life","2026-04-24",{"date":120,"type":40},"2026-05-01",{"date":122,"type":40},"2026-01-08",{"date":124,"type":20},"2029-07",{"name":126,"class":47},"Kalliopi Anna Poulia",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":48},"100514645","disparities-among-liver-transplant-patients-100514645","NCT05981196","Disparities Among Liver Transplant Patients","Individual and Structural-level Determinants Associated With Disparities Among Liver Transplant Patients","Inclusion Criteria:\n\n\\- Patients with end-stage liver, kidney, or cardiac dysfunction.\n\nExclusion Criteria:\n\n* Patients with more than one system with end stage organ dysfunction, dementia, cognitive or sensory impairment, prior solid organ transplant.\n* Patients with potential medical exclusions for transplant.","65 Years",{"count":136,"type":20},100,"OBSERVATIONAL","The purpose of this study is to inform healthcare interventions to reduce the disparities in liver transplant listing and in transplantation.",[61],[141,142,143,144,145],"Transplants","Transplantation","Healthcare Disparities","Minority Health","Communication","2026-04-14",{"date":148,"type":40},"2026-04-17",{"date":150,"type":40},"2023-11-15",{"date":152,"type":20},"2026-07",{"name":154,"class":47},"Mayo Clinic",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":168,"conditions":169,"keywords":177,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":48},"100613626","phase-1-immune-tolerance-induction-after-liver-transplantation-100613626","NCT07269041","Immune Tolerance Induction After Liver Transplantation","A Phase I Feasibility Study of HSPC Infusion Following Total Lymphoid Irradiation and Anti-thymocyte Globulin in Patients With a Pre-existing, Well-functioning HLA-matched Living-donor Liver Transplant to Induce Immune Tolerance.","iTILT","Recipient Inclusion Criteria:\n\n1. Males and females ages 18 years and older with a pre-existing liver transplant from a living donor with a donor-recipient match at 6 or more out of 12 alleles across the HLA-A, -B, -C, -DR, -DQ, and -DP loci, as determined by high-resolution HLA typing.\n2. Pre-existing living-donor liver transplant must be 12 months to 20 years from date of scheduled HSPC infusion.\n3. Agreement to participate in the study and ability to give informed consent.\n4. Liver biopsy within 4 weeks of enrollment without signs of rejection.\n5. Meets institutional criteria for HSPC infusion.\n6. Resides or is willing to stay within 3 hours distance from UCLA Medical Center by ground transportation for the first three months of the trial at the physician's discretion.\n7. No known contraindication to administration of rATG or radiation therapy.\n8. If subject is a female of reproductive potential (i.e., no documented absence of ovaries or uterus, history of tubal ligation, or post-menopausal status), subject must be confirmed not pregnant by a serum or urine pregnancy test and must agree to practice a reliable form of contraception including hormonal treatments, barrier methods or intrauterine device for at least 12 months following initiation of the tolerance protocol.\n\nRecipient Exclusion Criteria:\n\n1. Major ABO incompatibility with donor.\n2. Any of the following labs \\> 2.0 times the upper limit of normal on screening: AST, ALT, ALP, GGT or TBil.\n3. History of rejection with current HLA-matched liver transplant within the last year.\n4. History of GVHD following liver transplant.\n5. Positive Class II HLA Donor-Specific Antibody (DSA) or class I DSA specificity above 5,000 MFI at the time of the stem cell infusion.\n6. History of multi-organ transplantation, either simultaneous or as separate events.\n7. History of more than one liver transplant.\n8. Known allergy to rabbit proteins.\n9. History of a major post-transplant complication at investigator discretion.\n10. History of active malignancy within the past 5 years except for:\n\n    1. Malignancy that has not required treatment in the past on active surveillance.\n    2. Malignancy treated with curative intent with no known active disease \\>2 years before the first dose of study treatment and of low potential risk for recurrence.\n    3. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n    4. Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ, DCIS).\n11. Active bacterial, fungal or mycobacterial infection.\n12. Clinically significant viremia from EBV, CMV, HCV or HBV PCR test within the past 3 months.\n\n    1. Significant CMV viremia is defined as greater than or equal to 137 IU\u002FmL.\n    2. If CMV low-level viremia is detected, defined as 137 - 1,000 IU\u002FmL, patients may undergo subsequent testing up to twice per week and two consecutive negative results will allow for inclusion.\n13. Seropositivity for HIV 1 or 2 by 4th generation serum antibody\u002Fantigen testing, or HTLV I or II by serum antibody testing.\n14. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.\n15. Active extra-hepatic autoimmune disease requiring immunosuppression.\n16. Autoimmune disease was the indication for liver transplantation.\n17. Any condition that precludes the ability to give informed consent and\u002For places the subject at high risk for non-compliance with the safety monitoring requirements of the study.\n18. Received immunotherapy drugs, such as immune checkpoint inhibitors (e.g. pembrolizumab, nivolumab, and ipilimumab), tumor necrosis factor inhibitors, rituximab, or interleukin-2 within six months of the study treatment.\n19. Use of medications with known hepatotoxicity or potential to confound interpretation of liver function tests (e.g., methotrexate, isoniazid, amiodarone), unless reviewed and approved by the Principal Investigator and hepatology, and the subject has demonstrated stable liver function tests for ≥6 months while on the medication.\n20. Active hepatobiliary and pancreatic diseases:\n\n    1. History of chronic hepatobiliary or pancreatic disorders that may interfere with safety assessments or interpretation of protocol endpoints, including but not limited to primary sclerosing cholangitis (PSC), autoimmune hepatitis, primary biliary cholangitis (PBC), chronic pancreatitis, recurrent cholangitis, biliary strictures, biliary obstruction, untreated bile duct injury, hepatobiliary malignancy, or metabolic\u002Fgenetic liver disease (e.g., Wilson's disease, alpha-1 antitrypsin deficiency).\n    2. Active chronic liver diseases such as metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease.\n    3. Gallbladder diseases such as cholecystitis or symptomatic cholelithiasis.\n\nDonor Inclusion Criteria:\n\n1. Males and females ages 18 years and older meeting the HLA-matching requirements specified in the \"Recipient Inclusion Criteria\" above.\n2. Must meet the following criteria for HSPC donation:\n\n   1. Hgb: \\> 11 g\u002Fdl\n   2. Plt: \\> 80,000\u002FµL\n   3. WBC: \\> 3,000\u002FµL\n\nDonor exclusion criteria:\n\n1. Major ABO incompatibility with recipient.\n2. Medically unfit to tolerate peripheral blood apheresis (e.g., small body size, poor vascular access, not a suitable candidate for placement of a central catheter).\n3. Pregnant (confirmed by urine or serum pregnancy test) or lactating.\n4. Seropositivity for HIV 1 or 2 by 4th generation serum antibody\u002Fantigen testing, HTLV I or II by serum antibody testing.\n5. Active West Nile Virus infection.\n6. Active bacterial, fungal, mycobacterial or viral infection (including active hepatitis B and\u002For C).\n7. Psychiatric, addictive, neurological, or other disorder that compromises ability to give true informed consent for participation in this study\n8. Use of oral anticoagulants within two days of apheresis.\n9. History of active malignancy within the past 5 years except for:\n\n   1. Malignancy that has not required treatment in the past on active surveillance.\n   2. Malignancy treated with curative intent with no known active disease \\>2 years before the first dose of study treatment and of low potential risk for recurrence.\n   3. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n   4. Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ, DCIS).",{"count":164,"type":20},12,[166,167],"PHASE1","PHASE2","This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this \"Delayed Tolerance\" approach, achieving success in numerous kidney recipients now living drug-free. The process uses a conditioning regimen followed by donor stem cell infusion to retrain the immune system to accept the liver as \"self.\"",[26,170,171,172,173,174,175,176,29],"Immune Tolerance","Immune Tolerance\u002FDrug Effects","Graft Survival","Hematopoietic Stem Cell","Chimerism","Immunosuppression After Liver Transplantation","Immunosuppression Disorders",[26,170,178,174,179,180,181,182,183,184,185,186,187],"Hematopoietic Stem Cell Infusion","Mixed Chimerism","Total Lymphoid Irradiation","Antithymocyte Globulin","Immunosuppression Withdrawal","Living Donor Liver Transplant","Tolerance Induction","Delayed Immune Tolerance","Retroactive Immune Tolerance","Immunosuppression Toxicity","2026-03-10",{"date":190,"type":40},"2026-03-12",{"date":192,"type":40},"2026-02-20",{"date":194,"type":20},"2033-01",{"name":196,"class":47},"University of California, Los Angeles",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":204,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":48},"100624781","multidimensional-frailty-assessment-and-post-transplant-outcomes-in-liver-transplant-candidates-100624781","NCT07414095","Multidimensional Frailty Assessment and Post-Transplant Outcomes in Liver Transplant Candidates","Investigation of the Relationship Between Frailty, Sarcopenia, Malnutrition, and Psychosocial Parameters and Post-Transplant Outcomes in Liver Transplant Candidates","Inclusion Criteria:\n\n* Being listed as a liver transplant candidate\n* Age between 18 and 65 years\n* Ability to understand the Turkish language\n\nExclusion Criteria:\n\n* Presence of orthopedic and\u002For neurological problems severe enough to prevent completion of assessment tools\n* Inability to understand verbal commands\n* Being a recipient of multiple organ transplants\n* Presence of serious active extrahepatic malignancy",{"count":205,"type":20},60,"This study will evaluate frailty, nutrition, sarcopenia, and psychological health in people waiting for a liver transplant. The purpose is to understand how these factors affect outcomes before and after transplantation. By identifying patients at higher risk early, the study aims to support the development of better care programs in the future.\n\nParticipants will complete simple tests of physical strength, walking speed, and daily activity levels. Their nutrition and psychological well-being will also be assessed. The study will then look at how these results relate to medical scores used in liver disease and to outcomes after transplant, such as hospital stay, complications, or survival.\n\nAdults aged 18-65 years who are on the liver transplant waiting list and can understand Turkish are eligible to join.",[208,26,209],"End-Stage Liver Disease","Cirrhosis",[211,97,96,95,212],"Liver Transplant Candidates","Psychosocial Health","2026-02-12",{"date":215,"type":40},"2026-02-17",{"date":217,"type":40},"2025-12-15",{"date":219,"type":20},"2026-08",{"name":221,"class":47},"Izmir Bakircay University",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":232,"briefSummary":233,"conditions":234,"keywords":239,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":48},"100551068","phase-1-a-study-of-siplizumab-in-aild-and-lt-patients-100551068","NCT06455280","A Study of SIPLIZUMAB in AILD and LT Patients","A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)","SET-SAIL","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age ≥ 18 years old\n3. Clinical diagnosis of AIH and\u002For PSC\n4. Listed for liver transplantation\n5. Epstein-Barr virus (EBV) seropositive within 12 months of screening\n\nExclusion Criteria:\n\n1. Presence or history of significant liver disease other than AIH or PSC, including viral hepatitis, alcohol-related liver disease and biopsy-proven non-alcoholic steatohepatitis\n2. Prior transplant\n3. Listed for multiorgan transplant\n4. Acute liver failure\n5. Known malignancy, including cholangiocarcinoma and hepatocellular carcinoma\n6. Other investigational products in the last 30 days or 5 half lives\n7. Pregnant\u002Flactating or unwilling to use contraception\n8. Leukopenia (WBC less than 2,000\u002Fmm3\n9. Absolute lymphocyte count \\\u003C 200\u002Fmm3\n10. Sero-positive for HIV-1\n11. Hepatitis C Virus (HCV) antibody or RNA positive (within 6 months of screening)\n12. HBsAg, hepatitis B virus (HBV) DNA or HBcAb positive (within 6 months of screening)\n13. Alcohol use exceeding 30g\u002Fday for men or 20g\u002Fday for women, and\u002For known phosphatidylethanol (PETH) level \\>80 in the 3 months prior to LT\n14. Untreated latent TB infection as detected by QuantiFERON Gold Plus Interferon Gamma Release Assay (IGRA) (or current standard interferon gamma release assay for TB)\n15. Receipt of any live-attenuated vaccine within 2 months of transplant.\n\nADDITIONAL exclusion criteria to be reviewed at the time of transplant\n\n1. Renal failure with dialysis or with estimated glomerular filtration rate (eGFR) \\\u003C 30 at the time of LT\n2. Model for end-stage liver disease (MELD)-Na score \\>30\n3. Donor features of Donation after Cardiac Death (DCD), HCV Ab or nucleic acid testing (NAT+), HBcAb or HBsAg+, or blood types A, B, and O incompatible organ",{"count":231,"type":20},8,[166],"There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD. The purpose of this pilot, open-label phase 1 study is to determine the safety of siplizumab for induction in patients with AILD undergoing LT.\n\nUp to eight (8) subjects will receive siplizumab 0.6 mg\u002Fkg\u002Fdose on the day of transplant (Day 0) and Day 4 post-transplant, for a total of two doses.\n\nAll subjects will be followed in the study for 12 months post-LT.",[235,236,237,238,61,60],"Autoimmune Liver Disease","Liver Transplant Disorder","Autoimmune Hepatitis","Primary Sclerosing Cholangitis",[235,236,237,238,61,60],"2025-11-19",{"date":242,"type":40},"2025-11-24",{"date":244,"type":40},"2024-09-11",{"date":246,"type":20},"2028-03-31",{"name":248,"class":47},"Elizabeth C. Verna",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":255,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":21,"phases":258,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":278},"100347413","dissemination-of-the-donor-application-utilizing-social-media-to-identify-potential-live-organ-donors-100347413","NCT03803423","Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors","Inclusion Criteria:\n\n* At least 18 years of age\n* On the kidney-only or liver-only transplant waiting list at a collaborating center\n\nExclusion Criteria:\n\n* Younger than 18 years of age\n* Not on the kidney or liver transplant waiting list\n* On multiple organ transplant waiting lists",true,{"count":257,"type":20},1000,[23],"This study utilizes a web-based application to help patients on the organ transplant waitlist communicate patient's need for a living donor via social media and provide interested potential donors the opportunity to engage with the evaluation process.",[261,29],"End Stage Renal Disease",[263,264,265,266,267,268],"Live Donor Transplant","Social Media","Advocacy","Education","Living Donation","The Donor App","2025-11-06",{"date":271,"type":40},"2025-11-10",{"date":273,"type":40},"2017-11-27",{"date":275,"type":20},"2026-11-27",{"name":277,"class":47},"Johns Hopkins University",6,{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":48},"100475926","adverse-outcomes-and-mortality-in-liver-transplant-100475926","NCT05477277","Adverse Outcomes and Mortality in Liver Transplant","Inclusion Criteria:\n\n1. All patients with end-stage liver disease undergoing evaluation for liver transplantation\n2. Patient clinically indicated for MRI during transplant candidacy evaluation\n3. Adult\n\nExclusion Criteria:\n\n1\\. Contra indication to MRI",{"count":136,"type":20},[23],"Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.",[61,96,289,209],"Sarcopenic Obesity","2025-08-12",{"date":292,"type":40},"2025-08-15",{"date":294,"type":40},"2022-11-02",{"date":296,"type":20},"2027-07-01",{"name":154,"class":47},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":305,"targetDuration":4,"studyType":21,"phases":306,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":78},"100400610","phase-2-allogenic-hepatocyte-transplantation-into-periduodenal-lymph-nodes-100400610","NCT04496479","Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes","A Phase 2a, Open Label, Dose Escalation Study for Safety, Tolerability, and Efficacy of Hepatocyte Transplantation Into Periduodenal Lymph Nodes Among Subjects With End-Stage Liver Disease","Inclusion Criteria:\n\n1. Have read, understood, and signed the informed consent form (ICF).\n2. Adults of either gender and ages 18 to 70 years old with a diagnosis of ESLD due to alcohol, chronic hepatitis B virus (HBV) and\u002For hepatitis C virus (HCV) infections, autoimmune hepatitis, primary sclerosis cholangitis, primary biliary cirrhosis (cholangitis), cirrhosis as the result of Wilson disease, hemochromatosis, sarcoidosis and alpha 1 antitrypsin deficiency, cryptogenic cirrhosis, and nonalcoholic steatohepatitis cirrhosis with a MELD-Na score \\>10 and \\\u003C25 at screening.\n3. Subjects must have a body mass index (BMI) \\\u003C35.\n4. Subjects with HCV associated ESLD must have been treated and demonstrate 24 weeks of negative HCV ribonucleic acid (RNA).\n5. Subjects with HBV must be on stable therapy for 6 months and have HBV deoxyribonucleic acid \\\u003C500 c\u002FmL.\n6. Women of childbearing potential (WOCBP) or sexual partners of male subjects who are WOCBP must be able and willing to use at least 1 highly effective method of contraception during the study and for 1 month after the last study visit. A female subject is considered to be a WOCBP after menarche and until she is in a postmenopausal state for 12 months or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy; HMA, 2014). For the definition and list of highly effective methods of contraception, see Appendix 1.\n7. Has stable control of portal hypertension and upper gastrointestinal bleeding with medical therapy and\u002For endoscopic therapy.\n8. If the subject has undergone a TIPS procedure for the clinical management of portal hypertension, they must be stable after the successful TIPS procedure, and not experiencing serious complications from the TIPS procedure itself (e.g., infection and intractable hepatic encephalopathy).\n9. Has blood urea nitrogen (BUN) \\\u003C80 mg\u002FdL.\n10. Has an estimated glomerular filtration rate (eGFR) ≥45 mL\u002Fmin\u002F1.73 m2.\n11. Agrees to avoid alcohol consumption during the study.\n12. Is willing and able to comply with all requirements of the study protocol.\n\nExclusion Criteria:\n\n1. Has primary hepatic neoplasms (hepatocellular carcinoma and cholangiocarcinoma).\n2. Has active and\u002For uncontrolled severe infections requiring hospitalization and prolonged antimicrobial therapy.\n3. Has severe coagulopathy (international normalized ratio \\[INR\\] \\>2, and\u002For platelet count \\\u003C50,000\u002FμL).\n4. Has psychiatric and\u002For social issues that could lead to noncompliance.\n5. Has an extrahepatic neoplastic disease requiring active chemotherapy, immunotherapy, and\u002For surgical resection.\n6. Has previously treated neoplastic disease with less than a 2-year cancer free period.\n7. Pregnant and lactating women should not be in the study.\n8. Known hypersensitivity to human serum albumin.\n9. Subjects with uncontrolled hypertension (defined as a diastolic blood pressure of 110 mmHg or higher).\n10. Has recurrent\u002Fintractable ascites refractory to diuretics and requiring periodic large volume paracentesis.\n11. Has primary alcoholic liver disease and has not demonstrated abstinence for at least 24 weeks (6 months) prior to enrollment while attending mandatory rehab programs (e.g., Alcoholics Anonymous) and psychotherapy.\n12. Has grade 3 esophageal varices requiring the continuous use of propranolol and cannot afford to have this medication withheld and\u002For discontinued.\n13. Has a Child-Turcotte-Pugh (CTP) Class of C.\n14. Is receiving or plans to receive treatment with another investigational product or device.",{"count":164,"type":20},[167],"This Phase 2a clinical trial is a dose escalation study of the safety, tolerability, and efficacy of hepatocyte transplantation into lymph nodes via endoscopic ultrasound among subjects with end-stage liver disease.",[29],[310,311,312,142,313],"Allogeneic","Organogenesis","Hepatocyte","Liver Disease","2025-08-05",{"date":316,"type":40},"2025-08-08",{"date":318,"type":40},"2022-03-11",{"date":320,"type":20},"2027-12-30",{"name":322,"class":323},"LyGenesis, Inc.","INDUSTRY",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":21,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":343,"leadSponsor":345,"locationsCount":78},"100455085","hephospital-a-pilot-trial-of-a-hepatology-home-hospital-intervention-for-patients-with-advanced-liver-disease-100455085","NCT05205954","HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease","Inclusion Criteria:\n\n1. Adult patients ≥ 18 years old with diagnosis of cirrhosis based on histology, radiology, and\u002For elastography presenting to the emergency department or inpatient general medicine service\n2. Patients must have one of the following:\n\n   1. Ascites (requiring diuretics or serial large volume paracenteses)\n   2. Hepatic hydrothorax (requiring diuretics)\n   3. Hepatic encephalopathy (requiring medications)\n\nExclusion Criteria: All existing MGB home hospital criteria apply, with the following taking precedent for this specific condition\n\n1. History of solid organ transplantation\n2. On hemodialysis\n3. MELD score \\> 20\n4. Score \\\u003C10 on Simplified Animal Naming Test (S-ANT1)\n5. Current admission for hemodynamically significant GI bleeding or alcohol withdrawal\n6. Require routine administration of controlled substances\n7. Those deemed ineligible based on the MGH Home Hospital, inpatient medicine or hepatology clinician evaluation",{"count":331,"type":20},30,[23],"This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.",[209,61,94,335],"Liver Disease Chronic",[337,338],"Hospital at home","Home hospital","2025-07-21",{"date":341,"type":40},"2025-07-24",{"date":339,"type":40},{"date":344,"type":20},"2026-12-31",{"name":346,"class":47},"Massachusetts General Hospital",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":21,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":48},"100515962","liverpal-a-trial-of-inpatient-palliative-care-for-patients-with-advanced-liver-disease-100515962","NCT05998330","LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease","LiverPAL: A Randomized Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease","LiverPAL","Patient Inclusion Criteria:\n\n1. Hospitalized patient with a diagnosis of advanced liver disease, defined as cirrhosis with one of the following (new or ongoing) within the prior six months from date of consent:\n\n   * Ascites (requiring diuretics or serial large volume paracenteses)\n   * Spontaneous bacterial peritonitis\n   * Hepatic hydrothorax (requiring diuretics)\n   * Variceal bleed (with one or more occurrences)\n   * Overt hepatic encephalopathy (requiring medications)\n2. Ability to comprehend English\n\nPatient Exclusion Criteria:\n\n1. Prior history of liver transplantation\n2. Have uncontrolled hepatic encephalopathy, cognitive impairment, psychiatric disorder or other comorbid condition which the primary medical, hepatology, and\u002For transplant surgery teams believes prohibits the ability to provide informed consent\n3. Current or recent (within 5 years of receiving curative cancer treatment) history of extrahepatic malignancy (excluding non-melanoma skin cancer)\n4. Presence of hepatocellular carcinoma beyond Milan criteria\n5. Are already receiving hospice care\n6. Receive a score of \\\u003C10 on the Simplified Animal Naming Test\n\nCaregiver Inclusion Criteria\n\n1. Adult caregiver (≥ 18 years of age)\n2. A relative or friend identified by the patient upon whom the patient relies for help and who likely is to be present in-person during hospitalizations or clinic appointments, or willing to participate by phone\n3. Ability to comprehend English and can complete questionnaires\n\nCaregiver Exclusion Criteria\n\n1\\. Inability to comprehend English",{"count":356,"type":20},200,[23],"The goal of this clinical trial is to evaluate whether early integration of palliative care in the care of hospitalized patients with advanced liver disease (AdvLD) can improve patients' quality of life, physical symptoms, mood, and serious illness communication. Palliative care is a medical specialty focused on lessening (or \"palliating\") symptoms and assisting in coping with serious illness.",[335,61,209,60,360],"Advanced Cirrhosis","2025-07-14",{"date":363,"type":40},"2025-07-17",{"date":365,"type":40},"2023-09-20",{"date":367,"type":20},"2027-07",{"name":346,"class":47},{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":164},"100303294","functional-assessment-in-liver-transplantation-100303294","NCT03228290","Functional Assessment in Liver Transplantation","Functional Assessment in Liver Transplant Candidates (FrAILT) Study","FrAILT","Inclusion Criteria:\n\n* Adult (≥18 years old)\n* Are seen for the treatment of liver disease",{"count":378,"type":20},5000,"This will be a prospective cohort study of patients with liver disease. Subjects will undergo geriatric assessments of frailty, functional status, and disability using functional status measures at baseline and at every clinic visit in the pre-transplant setting. Subjects will also answer questions regarding quality of life, personality, and\u002For cognitive function. Subjects will again undergo assessments at every clinic visit through 12 months after transplant. Then, they will be followed annually.",[29],[209,382,27,97,383],"Liver","end stage","2025-07-02",{"date":386,"type":40},"2025-07-04",{"date":388,"type":40},"2011-10-12",{"date":390,"type":20},"2028-12-31",{"name":392,"class":47},"University of California, San Francisco",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":400,"enrollmentInfo":401,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":403,"conditions":404,"keywords":408,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":48},"100529451","ssm-predicts-outcomes-of-cld-inpatients-with-acute-liver-injury-100529451","NCT06173947","SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury","Spleen Stiffness Measurement Predicts Short-term Outcomes of Chronic Liver Disease Inpatients With Acute Liver Injury: a Prospective, Observational and Multicentre Study","Inclusion Criteria:\n\n1. Age between 18 years and 80 years\n2. Chronic liver diseases regardless of etiology\n3. Acute liver injury with total bilirubin ≥ 3 mg\u002Fdl regardless of inducement\n\nExclusion Criteria:\n\n1. Prior surgery of liver diseases before enrollment such as liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), splenectomy and partial splenic embolization\n2. Severe extrahepatic diseases such as chronic obstructive pulmonary disease level IV, chronic kidney disease with end-stage renal failure, myocardial infarction within 3 months before admission\n3. Receiving Immunosuppressive drugs for reasons rather than chronic liver diseases\n4. Diagnosis of hepatocellular carcinoma or other non-liver malignancies during screening period\n5. Serious mental illnesses such as anxiety, depressive disorders to obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD)\n6. The pregnant\n7. Jaundice due to biliary obstruction or cholestasis\n8. Unsuitable to participate in this study judging by investigators","80 Years",{"count":402,"type":20},411,"In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury. The present study aimed to establish an early diagnosis warning model for acute-on-chronic liver failure (ACLF) by SSM and investigate the effect of dynamic changes in SSM on the short-term prognosis (28-day, 90-day morbidity and mortality) of inpatients with CLD and acute liver injury.",[29,405,406,407],"Jaundice","Liver Dysfunction","Portal Hypertension",[29,409,410,411,407,405],"Chronic Liver Disease","Spleen Stiffness Measurement","Acute-on-Chronic Liver Failure","2025-05-19",{"date":414,"type":40},"2025-05-21",{"date":416,"type":40},"2024-01-01",{"date":418,"type":20},"2025-12-30",{"name":420,"class":47},"Nanfang Hospital, Southern Medical University",{"id":422,"slug":423,"hasResults":11,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":21,"phases":430,"briefSummary":431,"conditions":432,"keywords":434,"overallStatus":439,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":48},"100563420","effects-of-aerobic-and-resistance-exercises-on-inpatients-liver-transplantation-recipients-100563420","NCT06615934","Effects of Aerobic and Resistance Exercises on Inpatients Liver Transplantation Recipients","Comparing the Effects of Aerobic and Resistance Exercises With Routine Physiotherapy in Inpatients Immediately After Liver Transplantation on Muscle Strength, Functional and Aerobic Capacity, and Blood Biomarkers","Inclusion Criteria:\n\n1. Patients who undergo elective surgery after the approval of the liver transplant commission.\n2. Having an underlying liver disease with metabolic disorder (as determined by the Liver Transplantation Commission)\n3. Absence of transplantation of other organs\n4. No re-transplantation of the liver\n5. Age more than 18 years\n6. Ability to participate in initial evaluations\n7. Patient's ability to understand questionnaire questions\n\nExclusion Criteria:\n\n1. The patient's lack of satisfaction with continuing cooperation for any reason\n2. Re-transplantation up to 3 months after discharge\n3. Facing the patient with early allograft dysfunction or primary nonfunction\n4. Encountering the criteria of non-implementation of the intervention during 50% of the days of stay in the hospital or more\n5. Patients with Postoperative respiratory failure (Extubation \\> 48 hours)",{"count":429,"type":20},40,[23],"The prevalence of chronic liver disease and primary liver cancer is still increasing on a global scale, and so are their associated deaths.\n\nCompared to other diseases, death from liver disease often means premature death, because two-thirds of the lives lost are working years.\n\nLiver transplantation (LT) is an important and life-saving treatment option for the treatment of congenital metabolic disorders, acute liver failure, end-stage chronic liver disease (ESLD) and primary liver cancers.\n\nModern liver transplantation is characterized by significant improvements in post-transplant patient survival, graft survival, and quality of life.\n\nImpaired physical fitness of patients with end-stage liver disease often persists after liver transplantation and compromises post-transplant recovery.\n\nPrior to liver transplantation, excess ammonia taken up by skeletal muscle is a major metabolic driver of muscle wasting in end-stage liver disease and mainly inhibits the mTOR signaling pathway that supports muscle protein synthesis.\n\nBecause excess ammonia is no longer present after transplantation, recovery of muscle mass and function can be expected in patients. However, immunosuppression with calcineurin inhibitors that inhibit the mTOR signaling pathway may improve lethal length.\n\nIt is also thought that post-transplant treatment regimens contribute to delayed recovery of decreased bone mineral density and increased fracture risk.\n\nGreater muscle mass, as measured by creatinine clearance at 1 year after transplantation, was associated with longer recipient and allograft survival.\n\nThe results of previous studies indicate low cardiovascular fitness in patients after liver transplantation.\n\nSince after liver transplantation, cardiovascular diseases cause 19 to 42% of deaths not related to the liver, performing aerobic exercises to obtain and maintain cardiovascular fitness after liver transplantation can reduce the mortality rate. After transplanting, reduced significantly.\n\nConsidering the important role of the immune system in transplant rejection, the safety of sports training is very important in terms of not over-activating the immune system and endangering the life of the transplanted tissue. In previous studies related to exercise and immune system activity and inflammatory cytokines after transplantation, it has been shown that moderate exercise including aerobic and resistance exercises can inhibit inflammatory cytokines and have beneficial effects on the immune system.\n\nHigh levels of tumor necrosis factor-alpha (TNF-α) in the period after transplant surgery are associated with an increased risk of transplant rejection.\n\nAerobic exercise reduces levels of inflammatory cytokine TNF-α and markers of liver function in patients with chronic liver diseases.\n\nAccording to this evidence, it seems that doing sports exercises is effective in reducing the risk of transplant rejection and modulating the patient's immune system. Acute graft rejection occurs days to weeks after transplantation. The immune system can see the transplanted organ as foreign and attack it, destroy it and lead to transplant rejection.\n\nConsidering the mentioned benefits of exercise therapy after liver transplantation, it is possible that the early start of exercise therapy in the hospitalization phase leads to a reduction in the risk of transplant rejection and improvement of allograft residues in patients after liver transplantation.\n\nConsidering that the current evidence shows that there is no use of a specific rehabilitation protocol in the hospitalization phase of patients after liver transplantation, we intend to evaluate its effects with changes in the common physiotherapy program in these departments according to the specific conditions of these patients. In other words, despite the acceptable therapeutic effects, the use of a combined protocol of aerobic and resistance exercises in the hospitalization phase of these patients has not been reported so far.",[236,433,93],"Liver Transplant; Complications",[435,436,437,438],"physiotherapy","aerobic exercise","resistance exercise","liver transplant recipients","NOT_YET_RECRUITING","2024-09-26",{"date":442,"type":40},"2024-09-27",{"date":444,"type":20},"2024-10-01",{"date":446,"type":20},"2025-01-15",{"name":448,"class":47},"Tehran University of Medical Sciences",{"id":450,"slug":451,"hasResults":11,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":48},"100548220","vienna-hypothermic-oxygenated-machine-perfusion-study-100548220","NCT06418165","Vienna Hypothermic Oxygenated Machine Perfusion Study","Vienna Hypothermic Oxygenated Machine Perfusion for Liver Transplantation Study","VIHOMPS","Inclusion Criteria:\n\n* patients undergoing liver transplantation with the use of hypothermic oxygenated machine perfusion\n* age ≥ 18 years\n\nExclusion Criteria:\n\n* pregnancy\n* partial grafts\n* the anatomical integrity of the liver is not preserved in a way that makes the perfusion of the liver possible",{"count":458,"type":20},500,"In this observational cohort study data on all patients undergoing liver transplantation after hypothermic oxygenated machine perfusion at Medical University of Vienna will be prospectively recorded. Investigation of short- and long-term outcome in this cohort will be conducted.",[29,461],"Hepatocellular Carcinoma",[26,463],"Hypothermic Oxygenated Machine Perfusion","2024-05-15",{"date":466,"type":40},"2024-05-17",{"date":468,"type":40},"2018-01-01",{"date":470,"type":20},"2038-12-31",{"name":472,"class":47},"Medical University of Vienna",{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":11,"sex":16,"minAge":480,"maxAge":17,"enrollmentInfo":481,"targetDuration":4,"studyType":21,"phases":482,"briefSummary":483,"conditions":484,"keywords":485,"overallStatus":439,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":4},"100521396","salt-in-adolescents-with-end-stage-liver-disease-100521396","NCT06069050","SALT in Adolescents With End-stage Liver Disease","Sequential Adolescent Left Lateral Lobe Liver Transplantation in Adolescents With End-stage Liver Disease: a Single-center, Prospective, Single-arm Study","Inclusion Criteria:\n\n1. Age 7-18 years old;\n2. Patients with end-stage liver disease cannot obtain sufficient donor liver volume through conventional living donor liver transplantation;\n3. The general condition is good and can tolerate the follow-up operation plan;\n4. Guardians and children (over 14 years old) sign the informed consent.\n\nExclusion Criteria:\n\n1. Uncorrectable cardiopulmonary disease with excessive surgical risk\n2. Anatomical abnormalities precluding liver transplantation\n3. Patients with primary or secondary hepatic malignancies\n4. Patients with genetic metabolic diseases and their complications that cannot be completely cured by liver transplantation\n5. Persistent non-adherence to medical care\n6. Combined with AIDS and other diseases that affect surgery or tumor progression\n7. Other reasons that the researchers think are not suitable for participation.","7 Years",{"count":5,"type":20},[23],"End-stage liver disease is synonymous with advanced liver disease, liver failure, and decompensated cirrhosis, and their disease progression is generally irreversible. Unlike other end-stage diseases, liver transplantation is a definitive and potentially curative treatment for ESLD. However, due to clinical and social factors such as the shortage of donor livers, the number of patients who can be transplanted is far less than the number of waiting patients. About 14% of patients die each year while waiting, and about 10% of patients are too sick to be transplanted. Although changes in organ allocation policies and popularization of living donor liver transplantation have significantly reduced the waiting time and mortality of infant recipients under 2 years old. Pre-transplant mortality in children older than 6 years remains high. Therefore, expanding the donor liver pool is an urgent need to treat patients with adolescent end-stage liver disease (AESLD). In 2015, Norwegian scholars proposed a new surgical method, that is, resection and partial liver segment (2-3 segment) transplantation combined with delayed total hepatectomy can greatly alleviate the shortage of liver donors in the above patients.Based on the experience of clinical operation, our center proposes and designs the clinical research of sequential adolescent left lateral lobe liver transplantation (SALT) for the treatment of AESLD. On the basis of RAPID, the safety and efficacy of sequential juvenile left lateral lobe liver transplantation were evaluated for the above patients.",[61],[102,486,487],"two-stage liver resection","end stage liver dIsease","2023-10-03",{"date":490,"type":40},"2023-10-05",{"date":492,"type":20},"2023-10-20",{"date":494,"type":20},"2027-03-30",{"name":496,"class":47},"RenJi Hospital",{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":504,"enrollmentInfo":505,"targetDuration":4,"studyType":21,"phases":506,"briefSummary":507,"conditions":508,"keywords":510,"overallStatus":439,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":4},"100496906","liver-transplantation-with-two-stage-liver-resection-in-unresectable-liver-cancer--metastases-or-emd-stage-liver-disease-ltlr-lc-100496906","NCT05750329","Liver Transplantation With Two-stage Liver Resection in Unresectable Liver Cancer , Metastases or Emd-stage Liver Disease (LTLR-LC)","Clinical Study of Adjuvant Liver Transplantation Combined With Two-stage Hepatectomy for the Treatment of Patients With Unresectable Primary Hepatocellular Carcinoma, Colorectal Cancer With Liver Metastases, or End-stage Liver Disease: a Multicenter, Prospective, Single-arm Study","Inclusion Criteria:\n\n1. aged 18-75 years;\n2. patients with unresectable primary hepatocellular carcinoma or colorectal cancer with liver metastases who also meet the following criteria: tumor shrinkage (still unresectable) or no significant progression after a first-line chemotherapy regimen of 6-8 weeks; no other abdominal metastases or 1-3 resectable pulmonary metastases;\n3. patients with end-stage liver disease;\n4. preoperative Child classification of A or B, able to tolerate the subsequent surgical program\n5. Signed informed consent Note: One of the second or third criteria needs to be fulfilled and all the rest of the selection criteria need to be fulfilled\n\nExclusion Criteria:\n\n1. Extrahepatic tumor burden (except for resectable lung metastases) and\u002For macrovascular tumor infiltration\n2. Tumor progression during chemotherapy or important comorbidities that affect surgery\n3. Uncorrectable cardiopulmonary disease with high surgical risk\n4. Anatomical abnormalities that preclude liver transplantation\n5. Persistent non-compliance with medical care\n6. Combined with other diseases such as AIDS that affect surgery or tumor progression","75 Years",{"count":331,"type":20},[23],"Colon cancer and primary liver cancer are common malignant tumors with low survival rate worldwide, and unresectable primary liver cancer and colon cancer liver metastases have worse prognosis. End-stage liver disease is equated with advanced liver disease, liver failure and decompensated cirrhosis because they are generally irreversible. Liver transplantation is a treatment option for the above-mentioned patients and is expected to improve the prognosis of the patients, but the biggest problem faced by such patients is the shortage of donor livers. Recently, a new surgical modality, resection and partial liver segment 2-3 transplantation with delayed total hepatectomy (RAPID), can greatly alleviate these problems.Based on clinical surgical experience, our center proposes and designs a clinical study of adjuvant liver transplantation combined with two-stage hepatectomy in the treatment of patients with unresectable primary liver cancer, colorectal cancer liver metastases, or end-stage liver disease. By improvement of RAPID operation, the safety and efficacy of this treatment method in patients with those disease were evaluated.",[236,509,93],"Hepatic Cancer",[102,511],"Hepatectomy","2023-08-03",{"date":514,"type":40},"2023-08-07",{"date":516,"type":20},"2023-08",{"date":518,"type":20},"2026-12",{"name":496,"class":47},{"id":521,"slug":522,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":504,"enrollmentInfo":526,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":48},"100365418","real-world-study-of-end-stage-liver-disease-in-china-100365418","NCT04037995","Real World Study of End-stage Liver Disease in China","Inclusion Criteria:\n\n1. Informed consent of patients.\n2. Diagnosis of any of the following diseases: acute decompensation of cirrhosis, chronic and acute liver failure, chronic liver failure and hepatocellular carcinoma (stage III-IV)\n\nExclusion Criteria:\n\n1. HIV antibody positive and AIDS patients\n2. Serious psychiatric history, especially depression. Severe mental illness is defined as major depression or psychosis, suicide attempts, hospitalization due to mental illness or a period of disability due to mental illness.\n3. Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs.\n4. Patients with other malignant tumors (excluding those cured).\n5. Pregnant, lactating women or women of childbearing age who are ready to conceive.",{"count":527,"type":20},10000,"The aims of this study are exploring the current situation of end-stage liver disease in China, and the optimization of diagnosis and treatment. Liver cirrhosis often accompanied by a series of complications. Therefore, it is necessary to standardize the diagnosis and treatment of liver cirrhosis and its complications. End-stage liver disease mainly refers to the late stage of liver disease caused by various chronic liver damage. Its main feature is that liver function can not meet the physiological needs of human body. This study is a single-center, prospective and observational real-world study aimed at investigating and analyzing the current diagnosis and treatment of liver cirrhosis and end-stage liver disease in China.",[61,530],"Complication","2019-07-29",{"date":533,"type":40},"2019-07-30",{"date":535,"type":20},"2019-09-01",{"date":537,"type":20},"2029-09-01",{"name":539,"class":47},"Huashan Hospital",{"id":541,"slug":542,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":504,"enrollmentInfo":546,"targetDuration":4,"studyType":21,"phases":547,"briefSummary":548,"conditions":549,"keywords":553,"overallStatus":439,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":4},"100358421","abdominal-regional-perfusion-in-donation-after-cardiac-death-for-multi-organ-transplantation-100358421","NCT03946852","Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation","Recipient Criteria:\n\nInclusion Criteria- Indications for Liver transplant include decompensated Cirrhosis of any etiology Model for End-Stage Liver Disease (MELD) score \\> 15 with no contraindications to liver transplant as per conventional clinical practice.\n\nAcute or fulminant liver failure Advanced malignancy such as HCC, cholangiocarcinoma, neuroendocrine tumor, or other cancer meeting criteria for listing and exception points as per current clinical guidelines.\n\nExclusion Criteria-\n\n* Inadequate social support for liver transplant\n* Non-compliance with alcohol or narcotic cessation\n* Evidence of uncontrolled infection\n* Other untreated malignancy aside from those listed above\n* Physiologic evidence of frailty based on timed up and go, grip strength, 6 minute walk test, and cognitive testing.\n\nDonor Criteria:\n\nDCD donors offered via TGLN will be considered for assessment via abdominal regional perfusion based on the following parameters. These are in keeping with current criteria for abdominal organ donors.\n\n* Age: Up to 70 years of age within the initial evaluation period, with plans to expand to 75 y\u002Fo if initial results are favourable.\n* BMI: Donor BMI must be less than 30 for consideration\n* DCD donation criteria: Conventional criteria for DCD donation must be met, including no expectation for viable recovery, without meeting criteria for brain death, and expressed desire by family for organ donation.\n* Comorbidity: In the opinion of the on-call transplant surgeon, there should not be excessive comorbidity to exclude organ donation\n* Active infection: There should be no untreated infection.\n* Malignancy: Donors should have no evidence of active malignancy, or in the case of a treated malignancy there should be sufficient interval to rule out recurrence. In select cases, donors with tumors known to be indolent may be considered on a case by case basis.\n\nLiver transplant release Criteria:\n\nOne of the major advantages of ARP beyond reconditioning the organ prior to cold storage and transplant, is an opportunity to assess graft function in-situ prior to transplant. The existing literature supports the use of multiple readily available laboratory tests to evaluate graft function prior to transplant. Donor labs will be drawn every 30 minutes from the perfusion circuit to evaluate organ function.\n\n* Transaminase: Initial transaminases (AST and ALT) drawn at the start of perfusion must be less than 4 times the upper limit of normal and stay below this threshold throughout the reperfusion process to be considered for use with an absolute cut-off of 500\n* Lactate: Grafts will only be used if lactate levels do not rise during perfusion, ideal organs will have a decrease in serum lactate levels by 1.11 mmol\u002FL per hour\n* Macroscopic appearance: On clinical evaluation, there should be no evidence of fibrosis or cirrhosis and organs should not have a macroscopically steatotic appearance.",{"count":5,"type":20},[23],"The main purpose of this study is to increase the pool of organs available for donation by performing ARP to recondition donation after cardiac death (DCD) organs prior to transplantation. We will compare the outcomes of our ARP DCD liver transplants with historical data to determine the efficacy of this treatment compared to transplantation with standard DCD and donation after brain death (DBD) organs. We will also analyze biological samples from donors and recipients and compare them with outcome data in an effort to determine if any biological markers are able to predict the quality\u002Fsuccess of the grafts.",[433,550,209,551,552,29],"Ischemia Reperfusion Injury","Liver Cancer","Liver Metastases",[554,555,26,550],"abdominal regional perfusion","Donation after Cardiac Death","2019-05-09",{"date":558,"type":40},"2019-05-13",{"date":560,"type":20},"2019-06",{"date":562,"type":20},"2026-06",{"name":564,"class":47},"London Health Sciences Centre"]